|
Name |
Mollicellin I
|
Molecular Formula | C21H22O6 | |
IUPAC Name* |
2,9-dihydroxy-10-(hydroxymethyl)-4,7-dimethyl-3-(3-methylbut-2-enyl)benzo[b][1,4]benzodioxepin-6-one
|
|
SMILES |
CC1=CC(=C(C2=C1C(=O)OC3=C(O2)C=C(C(=C3C)CC=C(C)C)O)CO)O
|
|
InChI |
InChI=1S/C21H22O6/c1-10(2)5-6-13-12(4)19-17(8-16(13)24)26-20-14(9-22)15(23)7-11(3)18(20)21(25)27-19/h5,7-8,22-24H,6,9H2,1-4H3
|
|
InChIKey |
NTWOSLVOKRNGLX-UHFFFAOYSA-N
|
|
Synonyms |
Mollicellin I; 1016605-29-0; ALX4O68IJZ; 11H-Dibenzo(b,E)(1,4)dioxepin-11-one, 3,7-dihydroxy-4-(hydroxymethyl)-1,9-dimethyl-8-(3-methyl-2-buten-1-yl)-; UNII-ALX4O68IJZ; BS-1594; Q27273991; 2,9-dihydroxy-10-(hydroxymethyl)-4,7-dimethyl-3-(3-methylbut-2-enyl)benzo[b][1,4]benzodioxepin-6-one
|
|
CAS | 1016605-29-0 | |
PubChem CID | 24787299 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 370.4 | ALogp: | 4.6 |
HBD: | 3 | HBA: | 6 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 96.2 | Aromatic Rings: | 3 |
Heavy Atoms: | 27 | QED Weighted: | 0.413 |
Caco-2 Permeability: | -4.957 | MDCK Permeability: | 0.00001550 |
Pgp-inhibitor: | 0.091 | Pgp-substrate: | 0.62 |
Human Intestinal Absorption (HIA): | 0.091 | 20% Bioavailability (F20%): | 0.941 |
30% Bioavailability (F30%): | 0.003 |
Blood-Brain-Barrier Penetration (BBB): | 0.024 | Plasma Protein Binding (PPB): | 98.20% |
Volume Distribution (VD): | 0.507 | Fu: | 2.58% |
CYP1A2-inhibitor: | 0.718 | CYP1A2-substrate: | 0.207 |
CYP2C19-inhibitor: | 0.383 | CYP2C19-substrate: | 0.075 |
CYP2C9-inhibitor: | 0.536 | CYP2C9-substrate: | 0.55 |
CYP2D6-inhibitor: | 0.056 | CYP2D6-substrate: | 0.337 |
CYP3A4-inhibitor: | 0.173 | CYP3A4-substrate: | 0.176 |
Clearance (CL): | 13.823 | Half-life (T1/2): | 0.765 |
hERG Blockers: | 0.004 | Human Hepatotoxicity (H-HT): | 0.029 |
Drug-inuced Liver Injury (DILI): | 0.237 | AMES Toxicity: | 0.195 |
Rat Oral Acute Toxicity: | 0.926 | Maximum Recommended Daily Dose: | 0.782 |
Skin Sensitization: | 0.701 | Carcinogencity: | 0.251 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.89 |
Respiratory Toxicity: | 0.635 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004153 | 0.810 | D0Q0PR | 0.255 | ||||
ENC000921 | 0.780 | D0FA2O | 0.237 | ||||
ENC000884 | 0.738 | D07MGA | 0.229 | ||||
ENC002703 | 0.627 | D0AZ8C | 0.221 | ||||
ENC002595 | 0.583 | D04FBR | 0.221 | ||||
ENC005962 | 0.561 | D0O6KE | 0.220 | ||||
ENC005959 | 0.542 | D0K8KX | 0.220 | ||||
ENC003845 | 0.533 | D0WY9N | 0.220 | ||||
ENC003918 | 0.533 | D02PMO | 0.214 | ||||
ENC004154 | 0.495 | D06GCK | 0.214 |